18.16
4.37%
-0.83
After Hours:
18.675
0.515
+2.84%
HUTCHMED (China) Limited ADR stock is currently priced at $18.16, with a 24-hour trading volume of 185.30K.
It has seen a -4.37% decreased in the last 24 hours and a +9.07% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $18.92 pivot point. If it approaches the $17.92 support level, significant changes may occur.
Previous Close:
$18.99
Open:
$18.99
24h Volume:
185.30K
Market Cap:
$3.10B
Revenue:
$838.00M
Net Income/Loss:
$100.78M
P/E Ratio:
-72.64
EPS:
-0.25
Net Cash Flow:
$186.65M
1W Performance:
+10.06%
1M Performance:
+9.07%
6M Performance:
+6.82%
1Y Performance:
+22.04%
HUTCHMED (China) Limited ADR Stock (HCM) Company Profile
Name
HUTCHMED (China) Limited ADR
Sector
Phone
852 2121 8200
Address
Hutchison House, 22nd Floor 10 Harcourt Road, Central
HUTCHMED (China) Limited ADR Stock (HCM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
Aug-03-21 | Initiated | Jefferies | Buy |
Oct-02-20 | Initiated | Deutsche Bank | Buy |
Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-20-20 | Initiated | Goldman | Buy |
Nov-19-19 | Initiated | CLSA | Buy |
Oct-23-19 | Reiterated | BofA/Merrill | Buy |
Jul-05-19 | Initiated | Macquarie | Outperform |
View All
HUTCHMED (China) Limited ADR Stock (HCM) Latest News
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
GlobeNewswire Inc.
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
GlobeNewswire Inc.
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
GlobeNewswire Inc.
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
GlobeNewswire Inc.
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
GlobeNewswire Inc.
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga
HUTCHMED (China) Limited ADR Stock (HCM) Financials Data
HUTCHMED (China) Limited ADR (HCM) Revenue 2024
HCM reported a revenue (TTM) of $838.00 million for the quarter ending December 31, 2023.
HUTCHMED (China) Limited ADR (HCM) Net Income 2024
HCM net income (TTM) was $100.78 million for the quarter ending December 31, 2023.
HUTCHMED (China) Limited ADR (HCM) Cash Flow 2024
HCM recorded a free cash flow (TTM) of $186.65 million for the quarter ending December 31, 2023.
HUTCHMED (China) Limited ADR (HCM) Earnings per Share 2024
HCM earnings per share (TTM) was $0.55 for the quarter ending December 31, 2023.
About HUTCHMED (China) Limited ADR
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Cap:
|
Volume (24h):